{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:40Z","timestamp":1787027920082,"version":"build-2736575974"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n DISA","award":["(OA18\/078)"],"award-info":[{"award-number":["(OA18\/078)"]}]},{"name":"Fundaci\u00f3n DISA","award":["PIFUN 60\/17"],"award-info":[{"award-number":["PIFUN 60\/17"]}]},{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias","award":["(OA18\/078)"],"award-info":[{"award-number":["(OA18\/078)"]}]},{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias","award":["PIFUN 60\/17"],"award-info":[{"award-number":["PIFUN 60\/17"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) has a variable clinical evolution, with some patients living treatment-free for decades while others require therapy shortly after diagnosis. In a consecutive series of 217 CLL patients, molecular biomarkers with prognostic value (IGHV status, TP53 mutations, and cytogenetics), whose analysis is recommended prior to treatment start, were studied at diagnosis. Multivariate analyses identified prognostic variables for overall survival (OS) and time to first treatment (TTFT) and validated the CLL-IPI and IPS-E variables for all or early-stage patients (Rai 0\u20132\/Binet A), respectively. Unmutated IGHV was associated with shorter OS and TTFT, even for early-stage patients. Lymphocyte count was not statistically significant for TTFT of early-stage patients in multivariate analysis. Our results validate the prognostic value of IGHV mutational status at diagnosis for OS and TTFT, including for early stages. Our findings suggest a role for molecular and mutational analysis at diagnosis in future prospective studies.<\/jats:p>","DOI":"10.3390\/diagnostics12081802","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T21:20:59Z","timestamp":1658784059000},"page":"1802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages"],"prefix":"10.3390","volume":"12","author":[{"given":"Alexia","family":"Su\u00e1rez-Cabrera","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly Viviana","family":"Fiallo-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-2290","authenticated-orcid":false,"given":"Ruth","family":"Stuckey","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Luna","family":"Uroz-de la Iglesia","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanira","family":"Florido","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Lemes-Castellano","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-9266","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Perera-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3327-1299","authenticated-orcid":false,"given":"Hugo","family":"Luzardo-Henr\u00edquez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haridian","family":"de la Nuez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Fern\u00e1ndez-Caldas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"de la Iglesia","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"},{"name":"Department of Medical Sciences, Universidad de Las Palmas de Gran Canaria, 35001 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-1445","authenticated-orcid":false,"given":"Cristina","family":"Bilbao-Sieyro","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Gran Canaria Dr. Negr\u00edn, 35019 Las Palmas, Spain"},{"name":"Morphology Department, Universidad de Las Palmas de Gran Canaria, 35001 Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/leu.2010.208","article-title":"TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations","volume":"24","author":"Zenz","year":"2010","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/10428194.2011.631638","article-title":"Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia","volume":"53","author":"Seiffert","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"International CLL-IPI working group (2016). An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2019.228171","article-title":"A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia","volume":"105","author":"Cohen","year":"2019","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u2014Update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3324\/haematol.2009.005561","article-title":"Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages","volume":"94","author":"Gentile","year":"2009","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_26","unstructured":"(2022, June 03). NCCN Guidelines Version 3.2022. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Available online: https:\/\/www.nccn.org\/guidelines."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/8\/1802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:56:21Z","timestamp":1760140581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/8\/1802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["diagnostics12081802"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12081802","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]}}}